[New therapeutic opportunities in metastatic renal cell carcinoma]. / Neue Therapie-Optionen beim metastasierten Nierenzellkarzinom.
Praxis (Bern 1994)
; 98(9): 481-6, 2009 Apr 29.
Article
en De
| MEDLINE
| ID: mdl-19404907
Until recently metastatic renal cell carcinoma was considered refractory to the available therapies. A better understanding of the molecular biology and the introduction of targeted agents led to a significant improvement in the prognosis of patients with metastatic renal cell carcinoma. In this paper the molecular pathology, specifically the deregulation of the oxygen adaption mechanisms leading to tumorangiognesis will be presented. Based on these fundamental mechanisms the targeted agents will be introduced. These agents have been tested in randomized phase III trials in different clinical and prognostic situations. The results and the side-effects of sunitinib, sorafenib, temsirolimus, everolimus and bevacizumab treatment will be presented leading to a possible treatment algorithm.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Neoplasias Renales
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Humans
Idioma:
De
Revista:
Praxis (Bern 1994)
Asunto de la revista:
MEDICINA
Año:
2009
Tipo del documento:
Article
Pais de publicación:
Suiza